Biotech Values

[biomaven0]

>>Perceptive Edelman's interview was quite bullish too.

If you agree with his market analysis, we are talking a 10x return if the drug was successful. And I think all will concede this drug had a much better than 10% shot at success in this non-inferiority trial (which generally are easier than a superiority trial). So that made an investment a reasonable idea on a risk/reward basis.

Fortunately no position myself though.

Peter